GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>I thought you viewed news released after market close on Fridays as a danger sign.<

This is obviously an exception. Had GTC not had the regular quarterly CC scheduled for Monday morning, I think they would have waited until Monday to issue the PR. However, under the circumstances, it was good IR to release the news Friday to give investors time to assimilate it before the CC.

>Aren't government funded bioterror plays somewhat risky too, and subject to the winds and whims of political change?<

Of course they are. Fortunately, this is more of a problem for PharmAthene than it is for GTC.

>Any proof of concept is a good thing, but they won't have "real" clinical trials in humans for an anti-nerve gas agent, as that wouldn't pass muster before an ethics review board.<

This is a positive, not a negative. The FDA’s “animal rule” speeds clinical development substantially, as depicted in #msg-17587523. Regards, Dew